服務案例

當前位置︰首頁 > 服務案例 > 黑色素瘤> 逆轉癌癥的神奇靶向療法

  • 江苏福彩快3

    化名︰Mary Kate 年齡︰49 病癥︰黑色素瘤
    就診醫院︰ 哈佛大學醫學院教學附屬麻省總醫院 返回上頁

    患者參加了針對BRAF基因突變的靶向療法臨床試驗,腫瘤縮小了__,並成功地控制了黑色素瘤的進展。

    《郭軍,中國黑色素瘤診治指南2011版》與《美國國立癌癥研究院(NCI)》數據顯示︰

    黑色素瘤發病率︰中國1/10萬,美國21/10萬

    早中期黑色素瘤五年生存率︰中國38-__,美國達62.4-__

    晚期黑色素瘤五年生存率︰中國4.__,美國達15.__

    中國黑色瘤治療#1人 

    2-1.jpg

    郭軍教授

    北京腫瘤醫院腎癌黑色素瘤內科主任

    國際黑色素瘤研究聯盟委員

    簡歷︰

    現任北京腫瘤醫院、北京大學臨床腫瘤學院副院長,北京市腫瘤防治研究所副所長,腎癌黑色素瘤內科主任。中國臨床腫瘤協會(CSCO)執委會委員,中國臨床腫瘤協會(CSCO)黑色素瘤專家委員會主任委員,中國臨床腫瘤協會(CSCO)腎癌專家委員會主任委員,國際黑色素瘤研究聯盟(Society for Melanoma Research)亞太地區主席,國際黑色素瘤基金會(MIF)海外咨詢顧問。中國抗癌協會泌尿腫瘤分會常務委員《NCCN腎癌診治指南中國版》執筆人,《中國黑色素瘤診治共識》及《中國黑色素瘤診治指南》編寫組執筆人。臨床擅長︰腎癌、惡性黑色素瘤、膀胱癌、前列腺癌、腎上腺腫瘤綜合治療。

    近年發表的代表性論著(影響因子共61.64分)

    1. Guo J, Si L, Kong Y, Flaherty KT, Xu X, Zhu Y, Corless CL, Li L, Li H, Sheng X, Cui C, Chi Z, Li S, Han M, Mao L, Lin X, Du N, Zhang X, Li J, Wang B, Qin S. A Phase II, Open Label, Single-arm Trial of Imatinib Mesylate in Patients with Metastatic Melanoma Harboring c-Kit Mutation or Amplification. J Clin Oncol. 2011, June 20, 10.1200/JCO.2010.33.9275. (IF=18.96)

    2. Mao L, Si L, Chi Z, Cui C, Sheng X, Li S, Tang B, Guo J. A randomized phase II trial of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in high-risk acral melanoma patients. Eur J Cancer. 2011(47):1498-1503. (IF=4.943)

    3. Chi Z, Li S, Sheng X, Si L, Cui C, Han M, Guo J. Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: A study of 522 consecutive cases. BMC Cancer. 2011;11:85. (IF=3.153)

    4. Kong Y, Si L, Zhu Y, Xu XG, Corless CL, Flaherty K, Li L, Li H, Sheng X, Cui C, Chi Z, Li S, Han M, Mao L, Lu A, Guo J. Large Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma. Clin Cancer Res. 2011;17(7): 1684-1691. (IF=7.337)

    5. Si L, Kong Y, Xu X, Corless CL, Flaherty KT, Sheng X, Cui C, Chi Z, Zhu Y, Li S, Han M, Mao L, Guo J. Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort. Eur J Cancer.2011. (in press) (IF=4.943)

    6. Chen T, Guo J, Yang M, Zhu X, Cao X. Chemokine-containing exosomes are released from heat-stressed tumor cells via lipid raft-dependent pathway and act as efficient tumor vaccine. J Immunol. 2011;186:2219-28. (IF=5.745)

    7. Chen T, Guo J, Han C, Yang M, Cao X. Heat shock protein 70, released from heat-stressed tumor cells, initiates antitumor immunity by inducing tumor cell chemokine production and activating dendritic cells via TLR4 pathway. J Immunol. 2009;182:1449-59. (IF=5.745)

    8. Schadendorf D, Algarra SM, Bastholt L, Cinat G, Dreno B, Eggermont AM, Espinosa E, Guo J, Hauschild A, Petrella T, Schachter J, Hersey P. Immunotherapy of distant metastatic disease. Ann Oncol. 2009 Aug; 20 Suppl 6:vi41-50. (IF=5.647)

    9. Lu Si, Zhi-hong Chi, Xiang-qing Yuan, Chuan-liang Cui, Xi-nan Sheng, Jun Guo. A phase II study of fotemustine plus dacarbazine with dendritic cell vaccines as first-line therapy for Chinese patients with advanced acral lentiginous melanoma. Chinese Journal of Cancer Research,2009 Mar 21(1), 13-19. (IF=0.252)

    10. Guo J, Zhu J, Sheng X, Wang X, Qu L, Han Y, Liu Y, Zhang H, Huo L, Zhang S, Lin B, Yang Z. Intratumoral injection of dendritic cells in combination with local hyperthermia induces systemic antitumor effect in patients with advanced melanoma. Int J Cancer. 2007;120:2418-25. (IF=4.926)


    資料來源︰北京腫瘤醫院


    美國黑色素瘤治療#1人

    2-2.jpg

    F. Stephen Hodi, Jr.

    國際黑色素瘤研究聯盟創始人

    美國哈佛大學醫學院附屬布列根-丹娜法伯癌癥中心黑色素瘤治療中心主任

    美國哈佛大學醫學院副教授

    美國NCCN黑色素瘤診治指南制定者

    全球#1個研究人類惡性黑色素瘤的科學家

    簡歷︰

    Hodi博士獲美國內科醫學和醫學腫瘤學專業資格認證,擁有24年醫學從業經驗,是全球大的黑色素瘤研究協會——國際黑色素瘤研究聯盟的創始人,是全球#1個研究人類惡性黑色素瘤的科學家。美國NCCN (National Comprehensive Cancer Network)、美國臨床腫瘤學會(ASCO)、美國東部腫瘤協作組黑色素瘤委員會和國際癌癥生物治療學會的委員。1998年獲美國臨床科學家發展獎。美國NCCN黑色素瘤診治指南制定者(中國黑色素瘤診治指南是通過參考美國NCCN黑色素瘤診治指南修訂而成)。是黑色素瘤基因治療、免疫治療領域的全球專家。臨床擅長︰惡性黑色素瘤的靶向治療和免疫治療。

    近年發表的代表性論著(影響因子共782分)

    1. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012 Jun 28; 366(26):2443-54.( IF=53.298)

    2. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebb  C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 Aug 19; 363(8):711-23.( IF=53.298)

    3. Thompson JF, Hodi FS, Zembowicz A. Case records of the Massachusetts General Hospital. Case 2-2007. A 49-year-old woman with a pigmented lesion on the arm. N Engl J Med. 2007 Jan 18; 356(3):285-92. (IF=53.298)

    4. Flaherty KT, Hodi FS, Fisher DE. From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer. 2012; 12(5):349-61. (IF= 37.545)

    5. Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, MacConaill L, Macconnaill LE, Lee JC, Nicoletti R, Hatton C, Goyette M, Girard L, Majmudar K, Ziaugra L, Wong KK, Gabriel S, Beroukhim R, Peyton M, Barretina J, Dutt A, Emery C, Greulich H, Shah K, Sasaki H, Gazdar A, Minna J, Armstrong SA, Mellinghoff IK, Hodi FS, Dranoff G, Mischel PS, Cloughesy TF, Nelson SF, Liau LM, Mertz K, Rubin MA, Moch H, Loda M, Catalona W, Fletcher J, Signoretti S, Kaye F, Anderson KC, Demetri GD, Dummer R, Wagner S, Herlyn M, Sellers WR, Meyerson M, Garraway LA. High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007 Mar; 39(3):347-51.  (IF=35.532)

    6. Reidenberg MM, Hodi FS. A plea for prices in physician prescribing. JAMA. 1991 Dec 18; 266(23):3285.(IF=30.026)

    7. Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, Logan TF, Richards J, Michener T, Balogh A, Heller KN, Hodi FS. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012 May; 13(5):459-65.  (IF=22.589)

    8. McDermott DF, Sosman JA, Gonzalez R, Hodi FS, Linette GP, Richards J, Jakub JW, Beeram M, Tarantolo S, Agarwala S, Frenette G, Puzanov I, Cranmer L, Lewis K, Kirkwood J, White JM, Xia C, Patel K, Hersh E. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol. 2008 May 1; 26(13):2178-85.  (IF=18.372)

    9. Hodi FS, Friedlander P, Corless CL, Heinrich MC, Mac Rae S, Kruse A, Jagannathan J, Van den Abbeele AD, Velazquez EF, Demetri GD, Fisher DE. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol. 2008 Apr 20; 26(12):2046-51.  (IF=18.372)

    10. Haluska FG, Hodi FS. Molecular genetics of familial cutaneous melanoma. J Clin Oncol. 1998 Feb; 16(2):670-82.  IF=18.372

    11. Haluska FG, Hodi FS. . The molecular genetics of familial malignant melanoma. Journal of Clinical Oncology. 1998; 16:670-682.  IF=18.372

    12. Salgia R, Lynch T, Skarin A, Lucca J, Lynch C, Jung K, Hodi FS, Jaklitsch M, Mentzer S, Swanson S, Lukanich J, Bueno R, Wain J, Mathisen D, Wright C, Fidias P, Donahue D, Clift S, Hardy S, Neuberg D, Mulligan R, Webb I, Sugarbaker D, Mihm M, Dranoff G. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol. 2003 Feb 15; 21(4):624-30.  IF=18.372

    13. Salgia R, Lynch T, Skarin A, Lucca J, Lynch C, Jung K, Hodi FS, Jaklitsch M, Mentzer S, Swanson S, Lukanich J, Bueno R, Wain J, Mathiesen D, Wright C, Fidias P, Donahue D, Clift S, Hardy S, Neuberg D, Mulligan R, Webb I, Sugarbaker D, Mihm M, Dranoff G. . Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony stimulating factor augments anti-tumor immunity in patients with metastatic non-small cell lung carcinoma. Journal of Clinical Oncology. 2003; 21:624-630.  IF=18.372 

    14. Soiffer R, Hodi FS, Haluska F, Jung K, Gillessen S, Singer S, Tanabe K, Duda R, Mentzer S, Jaklitsch M, Bueno R, Clift S, Hardy S, Neuberg D, Mulligan R, Webb I, Mihm M, Dranoff G. . Vaccination with Irradiated, Autologous Melanoma Cells Engineered to Secrete Granulocyte-Macrophage Colony Stimulating Factor by Adenoviral Mediated Gene Transfer Augments Anti-tumor Immunity in Patients with Metastatic Melanoma. Journal of Clinical Oncology. 2003; 21:3343-3350.  IF=18.372

    15. Soiffer R, Hodi FS, Haluska F, Jung K, Gillessen S, Singer S, Tanabe K, Duda R, Mentzer S, Jaklitsch M, Bueno R, Clift S, Hardy S, Neuberg D, Mulligan R, Webb I, Mihm M, Dranoff G. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol. 2003 Sep 1; 21(17):3343-50.  IF=18.372

    16. Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, Humphrey R, Blumenstein B, Old L, Wolchok J. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst. 2010 Sep 22; 102(18):1388-97.  IF=13.757

    17. Jinushi M, Hodi FS, Dranoff G. Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines. Immunol Rev. 2008 Apr; 222:287-98. IF=11.148

    18. Jinushi M, Hodi FS, Dranoff G. Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. Proc Natl Acad Sci U S A. 2006 Jun 13; 103(24):9190-5. IF=9.681

    19. Luke JJ, Hodi FS. Vemurafenib and BRAF Inhibition: A New Class of Treatment for Metastatic Melanoma. Clin Cancer Res. 2012 Jan 1; 18(1):9-14.  IF=7.742

    20. Schatton T, Sch tte U, Frank NY, Zhan Q, Hoerning A, Robles SC, Zhou J, Hodi FS, Spagnoli GC, Murphy GF, Frank MH. Modulation of T-cell activation by malignant melanoma initiating cells. Cancer Res. 2010 Jan 15; 70(2):697-708. IF=7.856

    21. Fisher DE, Barnhill R, Hodi FS, Herlyn M, Merlino G, Medrano E, Bastian B, Landi MT, Landi TM, Sosman J. Melanoma from bench to bedside: meeting report from the 6th international melanoma congress. Pigment Cell Melanoma Res. 2010 Feb; 23(1):14-26. IF=5.059

    22. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebb  C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009 Dec 1; 15(23):7412-20. IF=7.742

    23. Ascierto PA, Grimaldi AM, Curti B, Faries MB, Ferrone S, Flaherty K, Fox BA, Gajewski TF, Gershenwald JE, Gogas H, Grossmann K, Hauschild A, Hodi FS, Kefford R, Kirkwood JM, Leachmann S, Maio M, Marais R, Palmieri G, Morton DL, Ribas A, Stroncek DF, Stewart R, Wang E, Mozzillo N, Marincola FM. FUTURE PERSPECTIVES IN MELANOMA RESEARCH. Meeting report from the "Melanoma Research: a bridge from Naples to the World. Napoli, December 5th-6 th2011". J Transl Med. 2012; 10:83.  IF=3.474

    24. Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A, Dilawari RA, Dimaio D, Guild V, Halpern AC, Hodi FS, Kelley MC, Khushalani NI, Kudchadkar RR, Lange JR, Lind A, Martini MC, Olszanski AJ, Pruitt SK, Ross MI, Swetter SM, Tanabe KK, Thompson JA, Trisal V, Urist MM. Melanoma. J Natl Compr Canc Netw. 2012 Mar 1; 10(3):366-400.  IF=4.409

    25. Alloo A, Garibyan L, Leboeuf N, Lin G, Werchniak A, Hodi FS, Flaherty KT, Lawrence DP, Lin JY. Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma. Arch Dermatol. 2012 Mar; 148(3):363-6. IF= 3.888

    26. Wu X, Zhu M, Fletcher JA, Giobbie-Hurder A, Hodi FS. The Protein Kinase C Inhibitor Enzastaurin Exhibits Antitumor Activity against Uveal Melanoma. PLoS One. 2012; 7(1):e29622. IF=4.092

    27. Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, H?kansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Melief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML. Defining the critical hurdles in cancer immunotherapy. J Transl Med. 2011; 9(1):214. IF=3.474

    28. Zhou J, Yuen NK, Zhan Q, Velazquez EF, Murphy GF, Giobbie-Hurder A, Hodi FS. Immunity to the melanoma inhibitor of apoptosis protein (ML-IAP; livin) in patients with malignant melanoma. Cancer Immunol Immunother. 2012 May; 61(5):655-65. IF=3.701

    29. O'Regan KN, Jagannathan JP, Ramaiya N, Hodi FS. Radiologic aspects of immune-related tumor response criteria and patterns of immune-related adverse events in patients undergoing ipilimumab therapy. AJR Am J Roentgenol. 2011 Aug; 197(2):W241-6. IF=2.775

    30. Wu X, Zhou J, Rogers AM, J?nne PA, Benedettini E, Loda M, Hodi FS. c-Met, epidermal growth factor receptor, and insulin-like growth factor-1 receptor are important for growth in uveal melanoma and independently contribute to migration and metastatic potential. Melanoma Res. 2012 Apr; 22(2):123-32.  IF=2.187

    31. Butler MO, Friedlander P, Milstein MI, Mooney MM, Metzler G, Murray AP, Tanaka M, Berezovskaya A, Imataki O, Drury L, Brennan L, Flavin M, Neuberg D, Stevenson K, Lawrence D, Hodi FS, Velazquez EF, Jaklitsch MT, Russell SE, Mihm M, Nadler LM, Hirano N. Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells. Sci Transl Med. 2011 Apr 27; 3(80):80ra34. IF=7.804

    32. Salama AK, Hodi FS. Cytotoxic T-lymphocyte-associated antigen-4. Clin Cancer Res. 2011 Jul 15; 17(14):4622-8. IF=7.742

    33. Schoenfeld J, Jinushi M, Nakazaki Y, Wiener D, Park J, Soiffer R, Neuberg D, Mihm M, Hodi FS, Dranoff G. Active immunotherapy induces antibody responses that target tumor angiogenesis. Cancer Res. 2010 Dec 15; 70(24):10150-60. IF=7.856

    34. Flaherty KT, Hodi FS, Bastian BC. Mutation-driven drug development in melanoma. Curr Opin Oncol. 2010 May; 22(3):178-83. IF=4.101

    35. Hodi FS, Dranoff G. The biologic importance of tumor-infiltrating lymphocytes. J Cutan Pathol. 2010 Apr; 37 Suppl 1:48-53. IF=1.561

    36. Hodi FS. Overcoming immunological tolerance to melanoma: Targeting CTLA-4. Asia Pac J Clin Oncol. 2010 Mar; 6 Suppl 1:S16-23. IF=0.585

    37. Coit DG, Andtbacka R, Bichakjian CK, Dilawari RA, Dimaio D, Guild V, Halpern AC, Hodi FS, Kashani-Sabet M, Lange JR, Lind A, Martin L, Martini MC, Pruitt SK, Ross MI, Sener SF, Swetter SM, Tanabe KK, Thompson JA, Trisal V, Urist MM, Weber J, Wong MK. Melanoma. J Natl Compr Canc Netw. 2009 Mar; 7(3):250-75. IF=4.409 

    38. Jiang X, Zhou J, Yuen NK, Corless CL, Heinrich MC, Fletcher JA, Demetri GD, Widlund HR, Fisher DE, Hodi FS. Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res. 2008 Dec 1; 14(23):7726-32. IF=7.742 

    39. Beadling C, Jacobson-Dunlop E, Hodi FS, Le C, Warrick A, Patterson J, Town A, Harlow A, Cruz F, Azar S, Rubin BP, Muller S, West R, Heinrich MC, Corless CL. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res. 2008 Nov 1; 14(21):6821-8. IF=7.742

    40. Hodi FS, Fisher DE. Adoptive transfer of antigen-specific CD4+ T cells in the treatment of metastatic melanoma. Nat Clin Pract Oncol. 2008 Dec; 5(12):696-7. IF=8

    41. Oble DA, Mino-Kenudson M, Goldsmith J, Hodi FS, Seliem RM, Dranoff G, Mihm M, Hasserjian R, Lauwers GY. Alpha-CTLA-4 mAb-associated panenteritis: a histologic and immunohistochemical analysis. Am J Surg Pathol. 2008 Aug; 32(8):1130-7. IF=4.352

    42.Hodi FS, Oble DA, Drappatz J, Velazquez EF, Ramaiya N, Ramakrishna N, Day AL, Kruse A, Mac Rae S, Hoos A, Mihm M. CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nat Clin Pract Oncol. 2008 Sep; 5(9):557-61. IF=8

    43.Sittler T, Zhou J, Park J, Yuen NK, Sarantopoulos S, Mollick J, Salgia R, Giobbie-Hurder A, Dranoff G, Hodi FS. Concerted potent humoral immune responses to autoantigens are associated with tumor destruction and favorable clinical outcomes without autoimmunity. Clin Cancer Res. 2008 Jun 15; 14(12):3896-905. IF=7.742

    44.Anderson KS, Ramachandran N, Wong J, Raphael JV, Hainsworth E, Demirkan G, Cramer D, Aronzon D, Hodi FS, Harris L, Logvinenko T, LaBaer J. Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer. J Proteome Res. 2008 Apr; 7(4):1490-9. IF=5.113

    45.Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, Macrae S, Nelson M, Canning C, Lowy I, Korman A, Lautz D, Russell S, Jaklitsch MT, Ramaiya N, Chen TC, Neuberg D, Allison JP, Mihm MC, Dranoff G. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A. 2008 Feb 26; 105(8):3005-10. IF=9.681 

    46.Lin WM, Baker AC, Beroukhim R, Winckler W, Feng W, Marmion JM, Laine E, Greulich H, Tseng H, Gates C, Hodi FS, Dranoff G, Sellers WR, Thomas RK, Meyerson M, Golub TR, Dummer R, Herlyn M, Getz G, Garraway LA. Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res. 2008 Feb 1; 68(3):664-73. IF=7.856

    47.Hodi FS. Cytotoxic T-lymphocyte-associated antigen-4. Clin Cancer Res. 2007 Sep 15; 13(18 Pt 1):5238-42. IF=7.742

    48.Butler MO, Lee JS, Ans n S, Neuberg D, Hodi FS, Murray AP, Drury L, Berezovskaya A, Mulligan RC, Nadler LM, Hirano N. Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell. Clin Cancer Res. 2007 Mar 15; 13(6):1857-67. IF=7.742

    49.Hodi FS. Well-defined melanoma antigens as progression markers for melanoma: insights into differential expression and host response based on stage. Clin Cancer Res. 2006 Feb 1; 12(3 Pt 1):673-8. IF=7.742

    50.Hodi FS, Dranoff G. Combinatorial cancer immunotherapy. Adv Immunol. 2006; 90:341-68. IF=5.762

    51.Roberts JD, Niedzwiecki D, Carson WE, Chapman PB, Gajewski TF, Ernstoff MS, Hodi FS, Shea C, Leong SP, Johnson J, Zhang D, Houghton A, Haluska FG. Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901. J Immunother. 2006 Jan-Feb; 29(1):95-101. IF=3.267

    52.Linette GP, Zhang D, Hodi FS, Jonasch EP, Longerich S, Stowell CP, Webb IJ, Daley H, Soiffer RJ, Cheung AM, Eapen SG, Fee SV, Rubin KM, Sober AJ, Haluska FG. Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunity. Clin Cancer Res. 2005 Nov 1; 11(21):7692-9. IF=7.742

    53.Hodi FS, Granter S, Antin J. Withdrawal of immunosuppression contributing to the remission of malignant melanoma: a case report. Cancer Immun. 2005; 5:7. IF=3.701 

    54.Katz KA, Jonasch E, Hodi FS, Soiffer R, Kwitkiwski K, Sober AJ, Haluska FG. Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute. Melanoma Res. 2005 Feb; 15(1):77-82. IF=2.187

    55.Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, Davis T, Henry-Spires R, MacRae S, Willman A, Padera R, Jaklitsch MT, Shankar S, Chen TC, Korman A, Allison JP, Dranoff G. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A. 2003 Apr 15; 100(8):4712-7. IF=9.681

    56.Mollick JA, Hodi FS, Soiffer RJ, Nadler LM, Dranoff G. MUC1-like tandem repeat proteins are broadly immunogenic in cancer patients. Cancer Immun. 2003 Mar 17; 3:3. IF=3.701

    57.Schmollinger JC, Vonderheide RH, Hoar KM, Maecker B, Schultze JL, Hodi FS, Soiffer RJ, Jung K, Kuroda MJ, Letvin NL, Greenfield EA, Mihm M, Kutok JL, Dranoff G. Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. Proc Natl Acad Sci U S A. 2003 Mar 18; 100(6):3398-403. IF=9.681

    58.Schmollinger JC, Vonderheide RH, Hoar, KM, Maecker B, Schultze JL, Hodi FS, Soiffer RJ, Jung K, Kuroda MJ, Letvin NL, Greenfield EA, North PE, Mihm M, Kutok JL, Dranoff G. . The inhibitor of apoptosis protein ML-IAP is a target for immune mediated tumor destruction. Proceedings of the National Academy of Sciences of the United States of America. 2003; 100:3398-3403. IF=9.681

    59.Krackhardt AM, Witzens M, Harig S, Hodi FS, Zauls AJ, Chessia M, Barrett P, Gribben JG. Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX. Blood. 2002 Sep 15; 100(6):2123-31. IF=9.898

    60.Hodi FS, Soiffer RJ, Clark J, Finkelstein DM, Haluska FG. Phase II study of paclitaxel and carboplatin for malignant melanoma. Am J Clin Oncol. 2002 Jun; 25(3):283-6. IF=2.005

    61.Tsao H, Millman P, Linette GP, Hodi FS, Sober AJ, Goldberg MA, Haluska FG. Hypopigmentation associated with an adenovirus-mediated gp100/MART-1-transduced dendritic cell vaccine for metastatic melanoma. Arch Dermatol. 2002 Jun; 138(6):799-802. IF=3.888

    62.Hodi FS, Schmollinger JC, Soiffer RJ, Salgia R, Lynch T, Ritz J, Alyea EP, Yang J, Neuberg D, Mihm M, Dranoff G. ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction. Proc Natl Acad Sci U S A. 2002 May 14; 99(10):6919-24. IF=9.681

    63.Krackhardt AM, Witzens M, Harig S, Hodi FS, Zauls, AJ, Chessia M, Barrett P, Gribben JG. . Identification of novel antigens in chronic lymphocytic leukemia by SEREX: Assessment of their potential as targets for immunotherapeutic approaches. Blood. 2002; 100:2123-2131. IF=9.898

    64.Jonasch E, Kumar UN, Linette GP, Hodi FS, Soiffer RJ, Ryan BF, Sober AJ, Mihm MC, Tsao H, Langley RG, Cosimi BA, Gadd MA, Tanabe KK, Souba W, Haynes HA, Barnhill R, Osteen R, Haluska FG. Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma. Cancer J. 2000 May-Jun; 6(3):139-45. IF=3.256

    65.Soiffer R, Lynch T, Mihm M, Jung K, Rhuda C, Schmollinger JC, Hodi FS, Liebster L, Lam P, Mentzer S, Singer S, Tanabe KK, Cosimi AB, Duda R, Sober A, Bhan A, Daley J, Neuberg D, Parry G, Rokovich J, Richards L, Drayer J, Berns A, Clift S, Cohen LK, Mulligan RC, Dranoff G. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 1998 Oct 27; 95(22):13141-6. IF=9.681

    66.Hodi FS, Dranoff G. Genetically modified tumor cell vaccines. Surg Oncol Clin N Am. 1998 Jul; 7(3):471-85. IF=1.117

    67.Watkins DI, Chen ZW, Hughes AL, Hodi FS, Letvin NL. Genetically distinct cell populations in naturally occurring bone marrow-chimeric primates express similar MHC class I gene products. J Immunol. 1990 May 15; 144(10):3726-35. IF=5.788

    68.Watkins DI, Shadduck JA, Hodi FS, Stone ME, Letvin NL. Use of cDNA probes specific for the human MHC class II beta loci for tissue-typing nonhuman primates at their class II beta loci. Transplantation. 1989 Jul; 48(1):170-3. IF=4.003

    69.Watkins DI, Hodi FS, Letvin NL. A primate species with limited major histocompatibility complex class I polymorphism. Proc Natl Acad Sci U S A. 1988 Oct; 85(20):7714-8. IF=9.681

    70.Daniel MD, Letvin NL, Sehgal PK, Schmidt DK, Silva DP, Solomon KR, Hodi FS, Ringler DJ, Hunt RD, King NW, et al. Prevalence of antibodies to 3 retroviruses in a captive colony of macaque monkeys. Int J Cancer. 1988 Apr 15; 41(4):601-8. IF=5.444

    71.Daniel MD, Letvin NL, Sehgal PK, Schmidt DK, Silva DP, Solomon KR, Hodi FS Jr, Ringler DJ, Hunt RD, King NW, Desrosiers RC. Prevalance of antibodies to three retroviruses in a captive colony of Macaque monkeys. International Journal of Cancer. 1988; 41:601-8. IF=5.444


    資料來源︰美國哈佛大學醫學院附屬布列根-丹娜法伯癌癥中心


    國際黑色素瘤專家簡介

    2-3.jpg

    全球大的黑色素瘤研究協會——國際黑色素瘤研究聯盟主席

    美國哈佛大學醫學院附屬麻省總醫院癌癥中心黑色素瘤治療中心主任

    麻省總醫院皮膚生物學研究中心主任

    美國哈佛大學醫學院教授

    簡歷︰

    Fisher教授獲美國內科醫學委員會內科醫學專業資格認證,是全球公認的皮膚學研究專家、臨床醫生和知名學者,擁有27年的醫學從業經驗,其研究重點為從分子學和遺傳學角度研究黑色素瘤和皮膚色素沉著的成因,其關于醫學、兒科和腫瘤學的專科培訓在哈佛大學醫學院內得到廣泛的推廣。

    成功案例

    姓名: Mary Kate

    年齡︰49

    當前診斷︰4期黑色素瘤

    分子指紋圖譜︰BRAF突變

    現狀︰4年生存者

    童年時期,Mary Kate和她的兄弟姐妹們就喜歡穿著T恤,帶著帽子,涂著防曬霜在海灘玩耍。他們的母親很早就告訴他們紅發白膚對陽光暴曬及皮膚癌更敏感些。Mary Kate長大後成了一名熱心的園丁,在戶外時她非常注意保護自己。但是終一生的謹慎也還是沒能戰勝基因,44歲時,Mary Kate檢查出患有黑色素瘤。現在,腫瘤基因或許是延緩甚至逆轉她的癌癥的關鍵。

    2005年的秋天,Mary Kate背上的一小顆痣檢查結果顯示對黑色素瘤呈陽性。盡管采用了免疫療法,手術以及化療,腫瘤還是擴散了。到2009年中,黑色素瘤通過淋巴系統擴散到 肺部和大腦,進展成了4期癌癥。

    Mary Kate知道自己身處逆境,但是在丈夫Michael及4個孩子(7至15歲)的支持下,她也知道她需要嘗試現有的任何治療方案。在麻省總醫院癌癥中心腫 瘤專家Donald Lawrence的指導下,Mary Kate參加了一系列的臨床試驗,包括馬里蘭州貝塞斯達的美國國立癌癥研究院的臨床試驗,但是效果都微乎其微。

    “今年一月份,我躺在馬里蘭州醫院的病床上,”Mary Kate回憶說,“當時我接到Lawrence醫生的電話,他想讓我再次去麻省總醫院參加一項新的臨床試驗,這項試驗的早期結果表明效果很好。”

    癌癥中心的醫務工作者們在Mary Kate的腫瘤中發現了一種基因突變,這種基因突變對于針對BRAF突變的基因定位藥物很敏感,而這種基因定位藥物剛好能抑制腫瘤的生長。盡管她當時臥床不起,身 體很虛弱,但是自從參加這項新的臨床試驗以來,Mary Kate感覺好了很多。她仍記得當時用手指觸摸頸部時,頸部的腫瘤明顯變小了。8周後,掃描結果顯示Mary Kate的腫瘤明顯變小了,縮小了__。

    這種口服藥物的副作用(包括對陽光的敏感度及關節痛)非常小。Mary Kate說相比較而言,使用這種藥物的所得遠遠大于所失去的。盡管她知道黑色素瘤以後還會復發 ,但是對于她已經取得的進展她非常感激,並且希望能研發出更多的基因定位藥物來控制她的黑色素瘤的進展。

    今年夏天,Mary Kate全家打算在馬薩諸塞州特魯的海灘度假3周。像往常一樣,她會用寬檐太陽帽和SPF70的防曬霜保護好自己和家人,並且定期找皮膚病專家做檢查。盡 管她要在海灘房屋的陰涼處享受新鮮的空氣,但是Mary Kate非常渴望听到驚濤拍岸的聲音和孩子們在海灘嬉戲的歡笑聲。

    附美國黑色素瘤患者生存率統計數據︰

    2-4.jpg

    官方來源鏈接︰http://seer.cancer.gov/statfacts/html/melan.html#survival


聯系醫學顧問

w66網址醫學顧問會盡快與您聯系

400-875-6700

出國看病費用評估

我想咨詢的疾病類型(單選)

    我的目標國家是(可多選)

      您想咨詢的疾病名稱

      您的稱呼

      您的手機號

      驗證碼

      其他想要了解的信息

      為減輕患者負擔,w66網址已經和超過半數美國癌癥排名前十的醫院達成深度合作協議,在國際自費患者常規折扣基礎上,額外為w66網址轉診患者爭取到5%-40%不等的專屬醫療費用優惠。